首页> 外国专利> Quinuclidine Derivatives, Pharmaceutical Composition and Method for the Treatment of Respiratory, Urological, or Gastrointestinal Disorders

Quinuclidine Derivatives, Pharmaceutical Composition and Method for the Treatment of Respiratory, Urological, or Gastrointestinal Disorders

机译:奎尼替丁衍生物,药物组合物和治疗呼吸系统,泌尿系统或胃肠道疾病的方法

摘要

A compound according to formula (I) wherein: custom-character file="US20030055080A1-20030320-P00900.TIF" wi="20" he="20" id="custom-character-00001"/is a phenyl ring, a C4 to C9 heteroaromatic compound containing one or more heteroatoms, or a naphthalenyl, 5,6,7,8-tetrahydronaphthalenyl or biphenyl group; R1, R2 and R3 each independently represent a hydrogen or halogen atom, or a hydroxy group, or a phenyl, -OR4, -SR4, -NR4R5, -NHCOR4, -CONR4R5, -CN, -NO2, -COOR4 or -CF3 group, or a straight or branched lower alkyl group which may optionally be substituted, for example, with a hydroxy or alcoxy group, wherein R4 and R5 each independently represent a hydrogen atom, straight or branched lower alkyl group, or together form an alicyclic ring; or R1 and R2 together form an aromatic, alicyclic or heterocyclic ring; n is an integer from 0 to 4; A represents a -CH2-, -CH=CR6, -CR6=CH-, -CR6R7-, -CO-, -O-, -S-, -S(O)-, SO2 or -NR6- group, wherein R6 and R7 each independently represent a hydrogen atom, straight or branched lower alkyl group, or R6 and R7 together form an alicyclic ring; m is an integer from 0 to 8; provided that when m=0, A is not -CH2-; p is an integer from 1 to 2 and the substitution in the azoniabicyclic ring may be in the 2, 3 or 4 position including all possible configurations of the asymmetric carbons; B represents a group of formula i) or ii): wherein R10 represents a hydrogen atom, a hydroxy or methyl group; and R8 and R9 each independently represents wherein R11 represents a hydrogen or halogen atom, or a straight or branched lower alkyl group and Q represents a single bond, -CH2-, -CH2-CH2-, -O-, -O-CH2-, -S-, -S-CH2- or -CH=CH-, and when i) or ii) contain a chiral centre they may represent either configuration; X represents a pharmaceutically acceptable a
机译:根据式(I)的化合物,其中:是苯环; C4至C9杂芳族化合物,其包含一个或多个杂原子,或萘基,5,6,7,8-四氢萘基或联苯基; R 1,R 2和R 3各自独立地表示氢或卤素原子,或羟基,或苯基,-OR 4,-SR 4,-NR 4 R 5,-NHCOR 4,-CONR 4 R 5,-CN,-NO 2,-COOR 4或-CF 3基团。 ;或直链或支链的低级烷基,其可任选地被例如羟基或烷氧基取代,其中R 4和R 5各自独立地代表氢原子,直链或支链的低级烷基,或一起形成脂环族环; R 1和R 2一起形成芳族,脂环族或杂环; n是0至4的整数; A代表-CH2-,-CH = CR6,-CR6 = CH-,-CR6R7-,-CO-,-O-,-S-,-S(O)-,SO2或-NR6-基团,其中R6 R 7和R 7各自独立地表示氢原子,直链或支链的低级烷基,或R 6和R 7一起形成脂环族环。 m是0至8的整数;假设当m = 0时,A不是-CH 2-; p是1至2的整数,并且在氮杂双环中的取代可以在2、3或4位,包括不对称碳的所有可能的构型; B代表式i)或ii)的基团:其中R 10代表氢原子,羟基或甲基; R 8和R 9各自独立地表示式中,R 11表示氢或卤素原子,或直链或支链的低级烷基,Q表示单键,-CH 2-,-CH 2 -CH 2-,-O-,-O-CH 2-。 ,-S-,-S-CH 2-或-CH = CH-,并且当i)或ii)包含手性中心时,它们可以代表任一种构型; X代表药学上可接受的

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号